Subsidiary to Develop Research and Business Opportunities

French immune-therapeutics developers Biomunex Pharmaceuticals has established a US subsidiary which will initially focus on facilitating research & development partnerships and business development activities.

“Following our recent licensing agreement with Sanofi for the generation and optimisation of bi- and multi-specific antibody therapeutics, we are excited about ramping up our R&D and partnering activities in the United States with the establishment of Biomunex Inc,” said Dr. Pierre-Emmanuel Gerard, CEO of the Paris-based parent company. “We are delighted to open our US subsidiary in Cambridge, MA, which probably represents the largest biotech cluster in the world, especially in the therapeutic antibody field. Biomunex’ ambition is to develop its product pipeline globally and this first step paves the way for US developments.”

“The establishment of the US subsidiary will contribute to our global R&D objectives by increasing discovery and development partnerships based on the BiXAb® technology with major US academic and industrial teams. Biomunex Inc will also accelerate the preclinical and clinical development of our proprietary BiXAb® antibodies,” added CSO Dr. Eugene Zhukovsky,